Trastuzumab emtansine, also known as T-DM1, is an antibody-drug conjugate used for the treatment of HER2-positive breast cancer. It combines the monoclonal antibody trastuzumab with the cytotoxic agent emtansine. In terms of patents, the provided sources shed light on different aspects of trastuzumab emtansine, including its composition, development, and intellectual property.
According to the information from DrugPatentWatch, trastuzumab emtansine is protected by several patents. One of the patents listed is US Patent 7,923,536, which covers the composition of trastuzumab emtansine and its use in treating HER2-positive cancers. This patent was granted in 2011 and is set to expire in 2028. Another patent mentioned is US Patent 8,853,260, which was granted in 2014 and also covers the composition and use of trastuzumab emtansine.
The Guide to Pharmacology provides biological information about trastuzumab emtansine, including its target and mechanism of action. It states that trastuzumab emtansine binds to the HER2 receptor, which is overexpressed in HER2-positive breast cancer cells. The antibody component of trastuzumab emtansine specifically targets the HER2 receptor, while the emtansine component acts as a cytotoxic agent, leading to cell death.
Additionally, a study published in the National Center for Biotechnology Information (NCBI) discusses the development and clinical use of trastuzumab emtansine. It highlights the significant therapeutic benefits of trastuzumab emtansine in HER2-positive breast cancer patients, particularly those who have previously received trastuzumab and taxane-based chemotherapy. The study also mentions that trastuzumab emtansine has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of HER2-positive metastatic breast cancer.
In conclusion, trastuzumab emtansine is protected by patents, including US Patent 7,923,536 and US Patent 8,853,260. It is an antibody-drug conjugate used for the treatment of HER2-positive breast cancer, targeting the HER2 receptor and inducing cell death. Trastuzumab emtansine has shown significant therapeutic benefits and has been granted orphan drug status by the FDA.
Sources:
[1] DrugPatentWatch: https://www.drugpatentwatch.com/p/biologics/ingredient/trastuzumab
[2] Guide to Pharmacology: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=biology&ligandId=6928
[3] NCBI: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465746/